07:33 AM EST, 11/11/2024 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.

The company said it targets to enroll about 20 evaluable patients in the trial.

The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.

Price: 2.7500, Change: -0.07, Percent Change: -2.48